Zoetis Inc.
ZTS evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $28.80B
What it means
What to watch
Prepared research question
What matters most for ZTS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZTS
Zoetis Inc. (ZTS) is a global animal health company that develops and commercializes medicines, vaccines, and diagnostics for livestock and companion animals, with a reported net income of $691.0M on revenue of $2,468.0M as of 2026-06-30 [sec].
Key risk: High debt leverage
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$28.80B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Zoetis Inc. (ZTS) is a global animal health company that develops and commercializes medicines, vaccines, and diagnostics for livestock and companion animals, with a reported net income of $691.0M on revenue of $2,468.0M as of 2026-06-30 [sec].
- Cash & equivalents of $1,476.0M, total revenue of $2,468.0M, and net income of $691.0M as of 2026-06-30 [sec].
- Total debt of $9,150.0M and shareholders' equity of $3,148.0M as of 2026-06-30 [sec].
- Launched Portela® (relfovetmab) in Canada and the EU in July 2026 as the first long-acting anti-NGF monoclonal antibody for feline osteoarthritis [news · 2026-07-22].
- Launched Lenivia® (izenivetmab injection) in Canada and the EU in July 2026 for canine osteoarthritis pain management [news · 2026-07-15].
- Received U.S. FDA Emergency Use Authorization for Simparica Trio to treat New World screwworm infestations in dogs [news · 2026-08-19].
What works
- Executed a balanced capital allocation strategy, returning more than $4 billion to shareholders through dividends and share repurchases [sec · filed 2026-04-08].
- Advanced a robust innovation pipeline including 12 blockbuster candidates, with expectations of a significant approval in a major market every year for several years [sec · filed 2026-04-08].
- Secured multiple new product approvals including Lenivia® for dogs, Portela® for cats, Avian Influenza vaccines, and a Bm86 tick vaccine for cattle [sec · filed 2026-04-08].
- CEO since 2020 delivered superior financial growth and industry-leading operating margins, launching 18 blockbuster products [sec · filed 2026-04-08].
What to weigh
- Total debt of $9,150.0M as of 2026-06-30 significantly exceeds shareholders' equity of $3,148.0M, indicating high leverage [sec].
- Lowered full-year 2026 revenue and earnings guidance, signaling a more cautious outlook [news · 2026-08-19].
- Shares fell 71% according to a September 2026 analysis, with noted 2030+ patent risks [news · 2026-09-30].
- Executed a $1.75 billion convertible senior notes offering with a 0.25% interest rate to facilitate a $1.3 billion stock repurchase, adding to debt [sec · filed 2026-04-08].
From the filings
Quoted directly from source documents.
Zoetis has a pipeline of 12 blockbuster candidates and expects regular major approvals.
“Advanced a robust and diversified innovation pipeline that includes 12 blockbuster candidates, which is expected to receive a significant approval in a major market every year for the next several years.”
SEC filings · April 8, 2026
Portela is the first long-acting anti-NGF mAb therapy for cats, launched in Canada and EU.
“Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for cats, designed to alleviate pain associated with osteoarthritis (OA) for up to three months with a single subcutaneous injection.”
News · July 22, 2026
Zoetis lowered its full-year 2026 revenue and earnings guidance.
“Zoetis lowered its full-year 2026 revenue and earnings guidance, signaling a more cautious outlook even as it expands the clinical reach of one of its flagship...”
News · August 19, 2026
Zoetis returned more than $4 billion to shareholders through dividends and share repurchases.
“Executed a balanced capital allocation strategy, returning more than $4 billion to shareholders through dividends and opportunistic share repurchases, reinforcing confidence in the Company's long-term growth prospects during a period of market volatility.”
SEC filings · April 8, 2026
Risks & what to watch (4)›
Key risks
- High debt leverage — Total debt of $9,150.0M far exceeds shareholders' equity of $3,148.0M as of 2026-06-30 [sec].
- Lowered 2026 guidance — Full-year 2026 revenue and earnings guidance was lowered, indicating a cautious outlook [news · 2026-08-19].
- Patent cliff risk post-2030 — Analysis notes 2030+ patent risks that could impact revenue [news · 2026-09-30].
- Stock price decline — Shares fell 71% according to a September 2026 analysis [news · 2026-09-30].
What to watch
- Execution of the 12-blockbuster pipeline and whether the expected annual major approvals materialize [sec · filed 2026-04-08].
- Commercial uptake of newly launched Portela and Lenivia in Canada and the EU [news · 2026-07-22] [news · 2026-07-15].
- Impact of the lowered 2026 revenue and earnings guidance on financial performance [news · 2026-08-19].
- Debt management and capital allocation strategy given the high total debt of $9,150.0M [sec].
Sources: News · SEC filings · Generated October 4, 2026 · How we verify sources →
Run Zoetis Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zoetis Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 3.79 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Financials
Short Interest
as of May 22, 2026- % of float
- 4.0%
- Days to cover
- 4.5
- Shares short
- 14,800,585
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZTS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Zoetis Inc.?
Zoetis Inc. (ZTS) is a global animal health company that develops and commercializes medicines, vaccines, and diagnostics for livestock and companion animals, with a reported net income of $691.0M on revenue of $2,468.0M as of 2026-06-30 [sec].
Who is the CEO of Zoetis Inc.?
Ms. Kristin C. Peck is the chief executive officer of Zoetis Inc. (ZTS).
Where is Zoetis Inc. headquartered?
Zoetis Inc. (ZTS) is headquartered in Parsippany, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.